Suppr超能文献

氧化磷脂与载脂蛋白(a)和脂蛋白(a)结合的决定因素。

Determinants of binding of oxidized phospholipids on apolipoprotein (a) and lipoprotein (a).

机构信息

Departments of Medicine, University of California, San Diego, La Jolla, CA.

出版信息

J Lipid Res. 2013 Oct;54(10):2815-30. doi: 10.1194/jlr.M040733. Epub 2013 Jul 4.

Abstract

Oxidized phospholipids (OxPLs) are present on apolipoprotein (a) [apo(a)] and lipoprotein (a) [Lp(a)] but the determinants influencing their binding are not known. The presence of OxPLs on apo(a)/Lp(a) was evaluated in plasma from healthy humans, apes, monkeys, apo(a)/Lp(a) transgenic mice, lysine binding site (LBS) mutant apo(a)/Lp(a) mice with Asp(55/57)→Ala(55/57) substitution of kringle (K)IV10)], and a variety of recombinant apo(a) [r-apo(a)] constructs. Using antibody E06, which binds the phosphocholine (PC) headgroup of OxPLs, Western and ELISA formats revealed that OxPLs were only present in apo(a) with an intact KIV10 LBS. Lipid extracts of purified human Lp(a) contained both E06- and nonE06-detectable OxPLs by tandem liquid chromatography-mass spectrometry (LC-MS/MS). Trypsin digestion of 17K r-apo(a) showed PC-containing OxPLs covalently bound to apo(a) fragments by LC-MS/MS that could be saponified by ammonium hydroxide. Interestingly, PC-containing OxPLs were also present in 17K r-apo(a) with Asp(57)→Ala(57) substitution in KIV10 that lacked E06 immunoreactivity. In conclusion, E06- and nonE06-detectable OxPLs are present in the lipid phase of Lp(a) and covalently bound to apo(a). E06 immunoreactivity, reflecting pro-inflammatory OxPLs accessible to the immune system, is strongly influenced by KIV10 LBS and is unique to human apo(a), which may explain Lp(a)'s pro-atherogenic potential.

摘要

氧化磷脂(OxPLs)存在于载脂蛋白(a)[apo(a)]和脂蛋白(a)[Lp(a)]上,但影响其结合的决定因素尚不清楚。在来自健康人类、猿类、猴子、载脂蛋白(a)/脂蛋白(a)转基因小鼠、赖氨酸结合位点(LBS)突变载脂蛋白(a)/脂蛋白(a)小鼠(天冬氨酸(55/57)→丙氨酸(55/57)取代 Kringle IV10)和各种重组载脂蛋白(a)[r-apo(a)]构建体的血浆中评估了 apo(a)/Lp(a)上 OxPLs 的存在。使用结合 OxPLs 的磷酸胆碱(PC)头基的抗体 E06,Western 和 ELISA 格式显示,OxPLs 仅存在于具有完整 KIV10 LBS 的 apo(a)中。通过串联液相色谱-质谱(LC-MS/MS),纯化的人 Lp(a)的脂质提取物中含有 E06-和非 E06-可检测的 OxPLs。17K r-apo(a)的胰蛋白酶消化显示,通过 LC-MS/MS 共价结合到 apo(a)片段上的含有 PC 的 OxPLs,可以用氨溶液皂化。有趣的是,在缺乏 E06 免疫反应性的 KIV10 中含有天冬氨酸(57)→丙氨酸(57)取代的 17K r-apo(a)中也存在含有 PC 的 OxPLs。总之,E06-和非 E06-可检测的 OxPLs 存在于 Lp(a)的脂质相中,并与 apo(a)共价结合。E06 免疫反应性反映了可被免疫系统接触的促炎 OxPLs,强烈受 KIV10 LBS 的影响,并且是人类 apo(a)所特有的,这可能解释了 Lp(a)的促动脉粥样硬化潜力。

相似文献

引用本文的文献

1
Lipoprotein(a) and panvascular disease.脂蛋白(a)与泛血管疾病。
Lipids Health Dis. 2025 May 24;24(1):186. doi: 10.1186/s12944-025-02600-y.
2
[Not Available].[无可用内容]。
Adv Lab Med. 2025 Mar 3;6(1):17-27. doi: 10.1515/almed-2024-0090. eCollection 2025 Mar.
4
Lipoprotein(a) as a Causal Risk Factor for Cardiovascular Disease.脂蛋白(a)作为心血管疾病的一个因果风险因素。
Curr Cardiovasc Risk Rep. 2025;19(1):8. doi: 10.1007/s12170-025-00760-1. Epub 2025 Feb 18.
6
Apolipoprotein B-containing lipoproteins in atherogenesis.动脉粥样硬化形成过程中含载脂蛋白B的脂蛋白
Nat Rev Cardiol. 2025 Jun;22(6):399-413. doi: 10.1038/s41569-024-01111-0. Epub 2025 Jan 2.
7
Lipoprotein(a) and cardiovascular disease.脂蛋白(a)与心血管疾病。
Biochem J. 2024 Oct 2;481(19):1277-1296. doi: 10.1042/BCJ20240037.
9
Therapeutic Gene Editing in Dyslipidemias.血脂异常的治疗性基因编辑
Rev Cardiovasc Med. 2024 Aug 15;25(8):286. doi: 10.31083/j.rcm2508286. eCollection 2024 Aug.

本文引用的文献

5
The plasminogen system in regulating stem cell mobilization.纤溶酶原系统在调节干细胞动员中的作用。
J Biomed Biotechnol. 2012;2012:437920. doi: 10.1155/2012/437920. Epub 2012 Oct 14.
6
Emerging therapeutic agents to lower lipoprotein (a) levels.新兴的脂蛋白(a)降低治疗药物。
Curr Opin Lipidol. 2012 Dec;23(6):560-8. doi: 10.1097/MOL.0b013e3283598d81.
7
Lipoprotein(a) metabolism: potential sites for therapeutic targets.脂蛋白(a)代谢:潜在的治疗靶点。
Metabolism. 2013 Apr;62(4):479-91. doi: 10.1016/j.metabol.2012.07.024. Epub 2012 Oct 4.
8
Lipoprotein(a): resurrected by genetics.脂蛋白(a):遗传学复活。
J Intern Med. 2013 Jan;273(1):6-30. doi: 10.1111/j.1365-2796.2012.02592.x. Epub 2012 Nov 12.

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验